Given the physiological functions of the FGF19-FGFR4 pathway in BA synthesis [84], the blockade of FGF19, FGFR4, or β-klotho, as a potential strategy to reduce the risk of cancer progression, would result in hepatic deregulation of BA synthesis. The gene discussed is FGF19; the disease is cancer.